Wednesday, January 11, 2017

BMS Vs. Merck (Keytruda®) Patent Spats: Delaware Federal Ono Litigation Status Conference Now Reset To February 23, 2017

Separately (but of greater import), I'll note that Keytruda® has been granted FDA accelerated review (with a May 10 expected action date) -- in lung cancers, in combination with chemotherapy. And that is good news; however, 45-Elect just said that drug companies are "getting away with murder" -- on drug pricing (in a live press conference in front of the world; not by late night tweet) -- and that is the pharma related bad news, of the morning. Expect more of that sort of mercurial (unthinking) volatility in remarks -- from the incoming Administration. [He may very well be a bigger threat to Kenilworth's revenues and business model -- than HRC ever was.]

In any event, here's the full text of the Ono Delaware order, of this morning. [Background on that litigation, here.]

. . . .The teleconference with Judge Thynge set for 1/17/17 at 10:00 AM Eastern Time has been rescheduled to 2/23/17 at 11:00 AM Eastern Time. Plaintiffs' counsel to initiate the teleconference call. Ordered by Judge Mary Pat Thynge on 1/11/17. . . .

Now you know. And I can scarcely imagine a more stark contrast, planet wide, than that seen in Chicago last night, compared to the press conference this morning. What has become of. . . statesmanship? I simply shudder to think -- how must the world now see us?


No comments: